Hutch News

Hutch News

Stories tagged 'non-hodgkin lymphoma'

One family, two sides of cancer

Basic scientist Dr. Wenying Shou’s parents were both treated for — and cured of — their cancers. The similarities end there.

Oct. 6, 2017 | By Rachel Tompa / Fred Hutch News Service

Both of Dr. Wenying Shou's parents were diagnosed with - and cured of - cancer. The similarities end there.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >


New integrated research center launches

Dr. Denise Galloway heads new collaborative center to study prevention and treatment of cancers linked to infectious agents

Aug. 10, 2017 | By Sabrina Richards / Fred Hutch News Service

Dr. Denise Galloway heads new collaborative center to research prevention and treatment of infection-related cancers

View story >


Hutch News

Nov. 21, 2016

Stories include: world-renowned oncologist recruited to Fred Hutch, lymphoma patients in remission after experimental immunotherapy and more.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Oct. 27, 2016

Good News: Halloran honored in Rome; Hutch nominated for nonprofit of the year; Obliteride amassed $2.4M.

View story >


Replenishing immune cells after remission

New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy

Oct. 17, 2016 | By Bill Briggs / Fred Hutch News Service

Scientists at Fred Hutch, Seattle Children’s Research Institute, and Technical University of Munich showed that activating a “kill switch” can turn off CAR T cells after doctors deem a cancer defeated, allowing normal B cells to again flourish.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.